Bronchodilators: current and future.
Copyright policy )Bronchodilators: current and future.
Bronchodilators are central in the symptomatic treatment of chronic obstructive pulmonary disease (COPD), although there is often limited reversibility of airflow obstruction. Three classes of bronchodilators (β2-agonists, antimuscarinic agents, methylxanthines) are currently available, which can be used individually, or in combination with each other or inhaled corticosteroids. Novel classes of bronchodilators have proved difficult to develop. The muscarinic β2-agonist molecules approach likely provides the best opportunity to develop combinations that combine corticosteroids with dual-bronchodilator activities, and thus potentially achieve better efficacy than is apparent with the current combination products that dominate the treatment of COPD.
β(2)-Agonist, Chronic Obstructive, Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO, Muscarinic Antagonists, Adrenal Cortex Hormone, Antimuscarinic agent, Pulmonary Disease, Pulmonary Disease, Chronic Obstructive, Choice of bronchodilator, Drug Therapy, Theophylline, Adrenal Cortex Hormones, Administration, Inhalation, Humans, Bronchodilator Agent, Adrenergic beta-Agonist, Chronic obstructive pulmonary disease, Methylxanthine, Adrenergic beta-Agonists, Choice of bronchodilators; Emerging bronchodilators; Adrenergic beta-Agonists; Humans; Antimuscarinic agents; β(2)-Agonists; Chronic obstructive pulmonary disease; Adrenal Cortex Hormones; Drug Therapy, Combination; Muscarinic Antagonists; Methylxanthines; Administration, Inhalation; Bronchodilator Agents; Theophylline; Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Muscarinic Antagonist, Emerging bronchodilator, Inhalation, Combination, Administration, Drug Therapy, Combination, Human
β(2)-Agonist, Chronic Obstructive, Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO, Muscarinic Antagonists, Adrenal Cortex Hormone, Antimuscarinic agent, Pulmonary Disease, Pulmonary Disease, Chronic Obstructive, Choice of bronchodilator, Drug Therapy, Theophylline, Adrenal Cortex Hormones, Administration, Inhalation, Humans, Bronchodilator Agent, Adrenergic beta-Agonist, Chronic obstructive pulmonary disease, Methylxanthine, Adrenergic beta-Agonists, Choice of bronchodilators; Emerging bronchodilators; Adrenergic beta-Agonists; Humans; Antimuscarinic agents; β(2)-Agonists; Chronic obstructive pulmonary disease; Adrenal Cortex Hormones; Drug Therapy, Combination; Muscarinic Antagonists; Methylxanthines; Administration, Inhalation; Bronchodilator Agents; Theophylline; Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Muscarinic Antagonist, Emerging bronchodilator, Inhalation, Combination, Administration, Drug Therapy, Combination, Human
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).64 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!